Sunitinib in metastatic renal cell carcimoma: A single-center experience.

Simple item page
dc.contributor.authorKrishna, V M
dc.contributor.authorNoronha, V
dc.contributor.authorPrabhash, K
dc.contributor.authorJoshi, A
dc.contributor.authorPatil, V
dc.contributor.authorBhosale, B
dc.contributor.authorRavi, T
dc.contributor.authorMenon, H
dc.contributor.authorGupta, S
dc.contributor.authorBanavali, S D
dc.contributor.authorBakshi, G
dc.contributor.authorTangaonkar, H B
dc.date.accessioned2013-10-07T04:49:32Z
dc.date.available2013-10-07T04:49:32Z
dc.date.issued2013-07
dc.description.abstractINTRODUCTION: Historically, metastatic renal cell carcinoma (RCC) has had poor prognosis; the outcomes have improved with the introduction of tyrosine‑kinase inhibitors, such as sunitinib. There is no reported literature from India on the use of sunitinib in metastatic RCC. We present an analysis of sunitinib at our institute over 4 years. MATERIALS AND METHODS: An unselected population of patients with metastatic or relapsed metastatic RCC receiving sunitinib was analyzed with respect to patient characteristics, response, toxicity, and outcomes. RESULTS: Fifty‑nine patients (51 males, 8 females) with a median age of 55 years were included in the study. Lungs and bones were the most common site of metastases. The patients received a median number of 4 cycles, with 23 patients requiring dose‑modification and 12 discontinuing therapy due to toxicity. Overall, 38 patients (65%) had CR, PR, or standard deviation while 14 had progression or death at initial evaluation. The median progression‑free survival (PFS) was 11.4 months and overall survival was 22.6 months. Hand–foot syndrome, fatigue, mucositis, skin rash, and vomiting were seen more often among our patients, whereas hypertension was not as common compared with previously published reports. CONCLUSION: Sunitinib is a viable option for the treatment of metastatic RCC and shows a comparable PFS in Indian patients. Although toxicity remains a concern, most of the adverse effects can be managed conservatively. Careful patient selection, tailoring the dose of therapy, adequate counseling, and careful follow‑up is essential for optimum therapy.en_US
dc.identifier.citationKrishna V M, Noronha V, Prabhash K, Joshi A, Patil V, Bhosale B, Ravi T, Menon H, Gupta S, Banavali S D, Bakshi G, Tangaonkar H B. Sunitinib in metastatic renal cell carcimoma: A single-center experience. Indian Journal of Cancer. 2013 July-Sept; 50(3): 268-273.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/148660
dc.language.isoenen_US
dc.source.urihttps://www.indianjcancer.com/article.asp?issn=0019-509X;year=2013;volume=50;issue=3;spage=268;epage=273;aulast=Krishnaen_US
dc.subjectMetastaticen_US
dc.subjectrenal cell canceren_US
dc.subjectsunitiniben_US
dc.subjecttargeted therapiesen_US
dc.subjecttyrosine kinase inhibitorsen_US
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Agents --therapeutic use
dc.subject.meshCarcinoma, Renal Cell --drug therapy
dc.subject.meshCarcinoma, Renal Cell --mortality
dc.subject.meshCarcinoma, Renal Cell --pathology
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshIndia
dc.subject.meshIndoles --therapeutic use
dc.subject.meshKidney Neoplasms --drug therapy
dc.subject.meshKidney Neoplasms --mortality
dc.subject.meshKidney Neoplasms --pathology
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPyrroles --therapeutic use
dc.subject.meshRetrospective Studies
dc.subject.meshTreatment Outcome
dc.titleSunitinib in metastatic renal cell carcimoma: A single-center experience.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijc2013v50n3p268.pdf
Size:
439.42 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Cancer